A private investment vehicle for a successful entrepreneur that was founded in 2012 and based in Western Europe is currently looking globally for therapeutics. The firm looks to make equity investments into therapeutics companies of up to $5 million initially for approximately 30% equity with additional capital reserved for follow-on rounds. The firm has no set number of allocations that it plans to make but is actively seeking new investments. The firm is looking for companies located around the globe.

The firm is looking for companies in the Therapeutics space developing small molecules or biologics. While the firm prefers companies in clinical trials they are also open to considering preclinical companies with strong animal data. The firm has special interest in diabetes and generally stays away from neurology and cancer, but is open to review all indications and therapeutic types.

The firm evaluates management on a case by case basis and prefers to work with management teams that have domain expertise and experience in their indication area. The firm generally looks to take a board seat following investment.

The venture investment arm of a Large Pharmaceutical Company with offices throughout the United States and Europe is looking to invest in 5-10 firms over the course of the next year. The firm covers a broad range of investments from seed through Series A, B, and C rounds.  The firm typically commits ~$25m over the life of an investment.

The firm invests in promising companies developing breakthrough innovations for high unmet need clinical problems. The firm broadly covers the healthcare market with investments across therapeutics, devices, diagnostics and healthcare services.  The firm will consider opportunities ranging from discovery concept through Phase II.  The fund is highly focused on technology innovation and will invest across all therapeutic areas and technology modalities.

The firm invests in pre-revenue, early stage companies, and prefers to invest in management teams with a foundation of expertise in their field.  In cases where the firm invests at the seed stage, the fund may be a very hands-on investor to help build the company, but is typically less hands-on when investing in mature companies.  As an early-stage investor the firm typically invests in privately-held companies, but also has the capability to invest in public companies and has had several portfolio companies go public subsequent to investment

A private equity firm Based in the Midwestern United States has invested over $800 million over its lifetime and is currently making investments out of its 12th $100 million fund. The firm is looking to make growth equity allocations of around $3-$5 million initially and up to $10 million over the lifetime of the investment. The firm will consider companies around the globe and is looking to make 4-5 investments over the next 12 months.

The firm is most interested in innovative medical technology companies that recently received FDA approval for their product. The firm has experience in medical devices, delivery devices, implantable devices, and reusable instruments so companies within those subsectors would be ideal however other medical technologies may also be considered. The firm also has interest in the Biotech R&D services sector within subsectors of CRO’s, diagnostic instrumentation and healthcare IT.

The firm is looking to invest in a company with approximately $5 million in yearly revenue with a strong management team. The firm will consider small public or private companies for investment and looks to acquire an active position on the company’s advisory board.

A private investment company established by a single high net worth individual is looking to make direct investments in the therapeutics space.  Based in New York City the firm manages an evergreen structure allowing it to have a very large range for investment size, capital structure, and holding period. The firm has no set number of allocations that it plans to make over the next 6-9 months and will evaluate all relevant opportunities on a case by case basis.

The firm is currently looking for US based companies in the therapeutics space and is open to considering both Biologics and Small Molecules. Companies with assets in phase II or later are of high interest, and companies in phase I that have some human efficacy data are also open to consideration. The firm is not interested in therapeutics areas with subjective endpoints such as pain and mental disorders.

The firm is looking for both private and micro-cap publicly held companies and evaluates management on a case-by-case basis. Taking a board seat is not a requirement for the firm and their involvement in the management of the firm varies based on the needs of the company. The firm is interested in both leading as well as co-investing in investment rounds.

A multi-family office based in the Greater Cincinnati area is looking to make direct investments in a variety of sectors including healthcare & life sciences.  Investments from this firm in early-stage companies are typically in the form of equity, whereas debt investments in later-stage companies may be considered.  The firm’s allocations are highly variable but are typically at least $3 million.  The firm primarily invests in US-based companies but Canada-based companies may also be considered.

Within the life science sector the firm has diverse interests, with a primary focus on medical devices and medical service providers (including biotech R&D services and healthcare IT companies).  Investments in therapeutic drug development may also be considered.  The firm is a generalist investor, and is open to investing in both preclinical and clinical-stage companies and considers opportunities on a case-by-case basis.  While the firm will consider investments in almost any indication, the firm prefers to invest in large markets and does not consider investment opportunities in rare diseases.

The Firm seeks to invest in solid management teams that have developed a product based on proprietary, patented technology.  While the firm does make investments into pre-revenue companies, they require that the company have a clearly defined path to revenue.

A life-sciences focused venture capital incubator accelerator based in San Francisco, California is looking to provide capital in the form of equity and convertible notes to seed and venture stage companies in the life science space. The firm can provide capital in the range of a few hundred thousand to $2million or more by leveraging its groups of angel syndicates. The firm invests in companies across the United States, Europe and Australia with a preference for California based companies. The firm looks to be involved in 3 new companies per year.

The firm is currently looking for companies in areas of Medical Technology/Devices, Therapeutics and Companion Diagnostics. In the Medical Device space the firm is open in terms of sector and indication and will consider firms that are in the development phase as well as those that have entered clinical trials. In the therapeutics space the firm is generally open as well however the firm is highly interested in areas of cell and gene therapy and oncology. For therapeutics the firm tends to get involved at the preclinical stage or during phase I of clinical trials.

The firm is looking for confident and experienced management teams. Given the early stage investment style that the firm has, they often work with management teams that are incomplete and have primarily academic backgrounds. Part of the value that the firm looks to add is helping firms fill in the gaps in their current management.

A family office based in the Central United States is looking to make equity investments into companies ranging from $.5 – $5 million with a preference for the middle of that range. The firm is also willing to co-invest with investors they either know well or are able to get a strong reference for.  The firm looks to invest in seed and series A rounds and looks to take a significant stake in the company’s equity.  The firm prefers to invest in companies that are not located in an areas highly saturated with venture capital. The firm plans to make 3-4 new investments over the next 12 months.

The family office is currently seeking companies in the therapeutics space and is open to both small molecules and biologics. The firm is looking for companies with pre-clinical assets that have some animal data and will also consider companies in early clinical trials if the valuation is appropriate. The firm is open to review all indications and currently is working with companies in the neurology and antibiotics space. The firm would also consider investments in companies developing high tech medical devices and diagnostics with a special interest in companies that are bridging the gap between Biology and Software. The firm is not interested in investing in drug discovery platforms.

The family office is looking for companies founded by passionate entrepreneurs pursuing novel science.   The firm takes an active investor role and generally looks to take a board seat following investment. The firm is a value-added investor, including providing virtual management team services to support our portfolio companies that don’t have a full team on board.  The firm is looking for companies with pre-money valuations under $5 million, with a special interest in opportunities valued under $2 million.